{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:48:36Z","timestamp":1792522116333,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T00:00:00Z","timestamp":1545004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2018M632141"],"award-info":[{"award-number":["2018M632141"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012150","name":"Shanghai Leading Academic Discipline Project","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012150","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai","doi-asserted-by":"publisher","award":["14ZR1424200"],"award-info":[{"award-number":["14ZR1424200"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1038\/s41416-018-0352-y","type":"journal-article","created":{"date-parts":[[2018,12,11]],"date-time":"2018-12-11T17:47:43Z","timestamp":1544550463000},"page":"317-330","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Interferon-alpha promotes immunosuppression through IFNAR1\/STAT1 signalling in head and neck squamous cell carcinoma"],"prefix":"10.1038","volume":"120","author":[{"given":"Hailong","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shufang","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingzhou","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,17]]},"reference":[{"key":"352_CR1","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359\u2013386 (2015).","journal-title":"Int. J. Cancer"},{"key":"352_CR2","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre, L. A. et al. Global cancer statistics, 2012. CA Cancer J. Clin. 65, 87\u2013108 (2015).","journal-title":"CA Cancer J. Clin."},{"key":"352_CR3","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1200\/JCO.2015.61.1509","volume":"33","author":"RL Ferris","year":"2015","unstructured":"Ferris, R. L. Immunology and immunotherapy of head and neck Cancer. J. Clin. Oncol. 33, 3293\u20133304 (2015).","journal-title":"J. Clin. Oncol."},{"key":"352_CR4","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris, R. L. et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 375, 1856\u20131867 (2016).","journal-title":"N. Engl. J. Med."},{"key":"352_CR5","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","volume":"17","author":"TY Seiwert","year":"2016","unstructured":"Seiwert, T. Y. et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 17, 956\u2013965 (2016).","journal-title":"Lancet Oncol."},{"key":"352_CR6","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan, M., Hopkins, A. & Jaffee, E. M. Tumor mutational burden and response rate to PD-1 inhibition. N. Engl. J. Med. 377, 2500\u20132501 (2017).","journal-title":"N. Engl. J. Med."},{"key":"352_CR7","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1158\/2326-6066.CIR-16-0237","volume":"5","author":"G Velasco De","year":"2017","unstructured":"De Velasco, G. et al. Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1\/PD-L1 inhibitors in cancer patients. Cancer Immunol. Res. 5, 312\u2013318 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"352_CR8","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3109\/08916930903510880","volume":"43","author":"P Rizza","year":"2010","unstructured":"Rizza, P., Moretti, F. & Belardelli, F. Recent advances on the immunomodulatory effects of IFN-alpha: implications for cancer immunotherapy and autoimmunity. Autoimmunity 43, 204\u2013209 (2010).","journal-title":"Autoimmunity"},{"key":"352_CR9","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/nri1604","volume":"5","author":"LC Platanias","year":"2005","unstructured":"Platanias, L. C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 5, 375\u2013386 (2005).","journal-title":"Nat. Rev. Immunol."},{"key":"352_CR10","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/imr.12001","volume":"250","author":"J Piehler","year":"2012","unstructured":"Piehler, J., Thomas, C., Garcia, K. C. & Schreiber, G. Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation. Immunol. Rev. 250, 317\u2013334 (2012).","journal-title":"Immunol. Rev."},{"key":"352_CR11","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/nm0609-612","volume":"15","author":"E Passegue","year":"2009","unstructured":"Passegue, E. & Ernst, P. IFN-alpha wakes up sleeping hematopoietic stem cells. Nat. Med. 15, 612\u2013613 (2009).","journal-title":"Nat. Med."},{"key":"352_CR12","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1182\/blood-2002-05-1521","volume":"101","author":"VS Cull","year":"2003","unstructured":"Cull, V. S., Tilbrook, P. A., Bartlett, E. J., Brekalo, N. L. & James, C. M. Type I interferon differential therapy for erythroleukemia: specificity of STAT activation. Blood 101, 2727\u20132735 (2003).","journal-title":"Blood"},{"key":"352_CR13","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1093\/neuonc\/nox051","volume":"19","author":"M Silginer","year":"2017","unstructured":"Silginer, M. et al. Autocrine activation of the IFN signaling pathway may promote immune escape in glioblastoma. Neuro. Oncol. 19, 1338\u20131349 (2017).","journal-title":"Neuro. Oncol."},{"key":"352_CR14","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/bjc.2017.442","volume":"118","author":"H Ma","year":"2018","unstructured":"Ma, H. et al. Interferon-alpha enhances the antitumour activity of EGFR-targeted therapies by upregulating RIG-I in head and neck squamous cell carcinoma. Br. J. Cancer 118, 509\u2013521 (2018).","journal-title":"Br. J. Cancer"},{"key":"352_CR15","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1016\/j.jcms.2016.07.033","volume":"44","author":"HL Ma","year":"2016","unstructured":"Ma, H. L., Jin, S. F., Tao, W. J., Zhang, M. L. & Zhang, Z. Y. Overexpression of stathmin\/oncoprotein 18 correlates with poorer prognosis and interacts with p53 in oral squamous cell carcinoma. J. Craniomaxillofac. Surg. 44, 1725\u20131732 (2016).","journal-title":"J. Craniomaxillofac. Surg."},{"key":"352_CR16","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1007\/s00018-004-4069-0","volume":"61","author":"MA Kuriakose","year":"2004","unstructured":"Kuriakose, M. A. et al. Selection and validation of differentially expressed genes in head and neck cancer. Cell Mol. Life Sci. 61, 1372\u20131383 (2004).","journal-title":"Cell Mol. Life Sci."},{"key":"352_CR17","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1038\/sj.onc.1207345","volume":"23","author":"A Cromer","year":"2004","unstructured":"Cromer, A. et al. Identification of genes associated with tumorigenesis and metastatic potential of hypopharyngeal cancer by microarray analysis. Oncogene 23, 2484\u20132498 (2004).","journal-title":"Oncogene"},{"key":"352_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-9-11","volume":"9","author":"CL Estilo","year":"2009","unstructured":"Estilo, C. L. et al. Oral tongue cancer gene expression profiling: Identification of novel potential prognosticators by oligonucleotide microarray analysis. BMC Cancer 9, 11 (2009).","journal-title":"BMC Cancer"},{"key":"352_CR19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1158\/0008-5472.CAN-03-2144","volume":"64","author":"MA Ginos","year":"2004","unstructured":"Ginos, M. A. et al. Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. Cancer Res. 64, 55\u201363 (2004).","journal-title":"Cancer Res."},{"key":"352_CR20","doi-asserted-by":"publisher","first-page":"e23452","DOI":"10.1371\/journal.pone.0023452","volume":"6","author":"CH Peng","year":"2011","unstructured":"Peng, C. H. et al. A novel molecular signature identified by systems genetics approach predicts prognosis in oral squamous cell carcinoma. PLoS ONE 6, e23452 (2011).","journal-title":"PLoS ONE"},{"key":"352_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-9-69","volume":"9","author":"H Ye","year":"2008","unstructured":"Ye, H. et al. Transcriptomic dissection of tongue squamous cell carcinoma. BMC Genomics 9, 69 (2008).","journal-title":"BMC Genomics"},{"key":"352_CR22","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).","journal-title":"Sci. Signal."},{"key":"352_CR23","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401\u2013404 (2012).","journal-title":"Cancer Discov."},{"key":"352_CR24","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1210\/jc.2016-1882","volume":"101","author":"S Fang","year":"2016","unstructured":"Fang, S. et al. IL-17A exacerbates fibrosis by promoting the proinflammatory and profibrotic function of orbital fibroblasts in TAO. J. Clin. Endocrinol. Metab. 101, 2955\u20132965 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"352_CR25","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.yexcr.2015.11.013","volume":"339","author":"SF Jin","year":"2015","unstructured":"Jin, S. F. et al. XL413, a cell division cycle 7 kinase inhibitor enhanced the anti-fibrotic effect of pirfenidone on TGF-beta1-stimulated C3H10T1\/2 cells via Smad2\/4. Exp. Cell Res. 339, 289\u2013299 (2015).","journal-title":"Exp. Cell Res."},{"key":"352_CR26","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.oraloncology.2017.11.024","volume":"76","author":"Y Wang","year":"2018","unstructured":"Wang, Y. et al. Oral cancer-derived exosomal NAP1 enhances cytotoxicity of natural killer cells via the IRF-3 pathway. Oral Oncol. 76, 34\u201341 (2018).","journal-title":"Oral Oncol."},{"key":"352_CR27","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13046-017-0575-4","volume":"36","author":"HL Ma","year":"2017","unstructured":"Ma, H. L. et al. Stathmin is overexpressed and regulated by mutant p53 in oral squamous cell carcinoma. J. Exp. Clin. Cancer Res. 36, 109 (2017b).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"352_CR28","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.7150\/jca.19486","volume":"8","author":"H Ma","year":"2017","unstructured":"Ma, H. et al. Interferon-alpha promotes the expression of cancer stem cell markers in oral squamous cell carcinoma. J. Cancer 8, 2384\u20132393 (2017a).","journal-title":"J. Cancer"},{"key":"352_CR29","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1158\/2159-8290.CD-11-0109","volume":"1","author":"A Bertotti","year":"2011","unstructured":"Bertotti, A. et al. A molecularly annotated platform of patient-derived xenografts (\u201cxenopatients\u201d) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 1, 508\u2013523 (2011).","journal-title":"Cancer Discov."},{"key":"352_CR30","doi-asserted-by":"publisher","first-page":"677","DOI":"10.7150\/thno.16357","volume":"7","author":"S Sun","year":"2017","unstructured":"Sun, S. et al. Targeting and egulating of an oncogene via nanovector delivery of MicroRNA using patient-derived xenografts. Theranostics 7, 677\u2013693 (2017).","journal-title":"Theranostics"},{"key":"352_CR31","doi-asserted-by":"publisher","first-page":"438","DOI":"10.15252\/emmm.201404580","volume":"7","author":"C Liu","year":"2015","unstructured":"Liu, C. et al. A DNA\/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency. EMBO Mol. Med. 7, 438\u2013449 (2015).","journal-title":"EMBO Mol. Med."},{"key":"352_CR32","doi-asserted-by":"publisher","first-page":"765","DOI":"10.4049\/jimmunol.166.2.765","volume":"166","author":"TJ Sayers","year":"2001","unstructured":"Sayers, T. J. et al. The restricted expression of granzyme M in human lymphocytes. J. Immunol. 166, 765\u2013771 (2001).","journal-title":"J. Immunol."},{"key":"352_CR33","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","volume":"4","author":"M Hidalgo","year":"2014","unstructured":"Hidalgo, M. et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 4, 998\u20131013 (2014).","journal-title":"Cancer Discov."},{"key":"352_CR34","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","volume":"167","author":"JL Benci","year":"2016","unstructured":"Benci, J. L. et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell 167, 1540\u20131554.e12 (2016).","journal-title":"Cell"},{"key":"352_CR35","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","volume":"19","author":"A Garcia-Diaz","year":"2017","unstructured":"Garcia-Diaz, A. et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep. 19, 1189\u20131201 (2017).","journal-title":"Cell Rep."},{"key":"352_CR36","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.imbio.2011.10.016","volume":"217","author":"J Chen","year":"2012","unstructured":"Chen, J. et al. Interferon-gamma-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway. Immunobiology 217, 385\u2013393 (2012).","journal-title":"Immunobiology"},{"key":"352_CR37","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.cell.2015.12.027","volume":"164","author":"CT Ng","year":"2016","unstructured":"Ng, C. T., Mendoza, J. L., Garcia, K. C. & Oldstone, M. B. Alpha and beta Type 1 interferon signaling: passage for diverse biologic outcomes. Cell 164, 349\u2013352 (2016).","journal-title":"Cell"},{"key":"352_CR38","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/j.1349-7006.2008.01051.x","volume":"100","author":"HM Chen","year":"2009","unstructured":"Chen, H. M. et al. Critical role for constitutive type I interferon signaling in the prevention of cellular transformation. Cancer Sci. 100, 449\u2013456 (2009).","journal-title":"Cancer Sci."},{"key":"352_CR39","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1038\/nm.2830","volume":"18","author":"BN Bidwell","year":"2012","unstructured":"Bidwell, B. N. et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat. Med. 18, 1224\u20131231 (2012).","journal-title":"Nat. Med."},{"key":"352_CR40","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ccell.2017.01.004","volume":"31","author":"KV Katlinski","year":"2017","unstructured":"Katlinski, K. V. et al. Inactivation of interferon receptor promotes the establishment of immune privileged tumor microenvironment. Cancer Cell 31, 194\u2013207 (2017).","journal-title":"Cancer Cell"},{"key":"352_CR41","doi-asserted-by":"publisher","first-page":"e349","DOI":"10.1097\/MD.0000000000000349","volume":"93","author":"LC Chang","year":"2014","unstructured":"Chang, L. C. et al. IFNAR1 is a predictor for overall survival in colorectal cancer and its mRNA expression correlated with IRF7 but not TLR9. Med. (Baltim.) 93, e349 (2014).","journal-title":"Med. (Baltim.)"},{"key":"352_CR42","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/MPA.0000000000000202","volume":"44","author":"S Booy","year":"2015","unstructured":"Booy, S. et al. Type I interferon receptor expression in human pancreatic and periampullary cancer tissue. Pancreas 44, 99\u2013105 (2015).","journal-title":"Pancreas"},{"key":"352_CR43","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1080\/08977190400000833","volume":"22","author":"J Bekisz","year":"2004","unstructured":"Bekisz, J., Schmeisser, H., Hernandez, J., Goldman, N. D. & Zoon, K. C. Human interferons alpha, beta and omega. Growth Factors 22, 243\u2013251 (2004).","journal-title":"Growth Factors"},{"key":"352_CR44","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1158\/2159-8290.CD-16-0850","volume":"7","author":"M Ruella","year":"2017","unstructured":"Ruella, M. et al. Overcoming the immunosuppressive tumor microenvironment of hodgkin lymphoma using chimeric antigen receptor T cells. Cancer Discov. 7, 1154\u20131167 (2017).","journal-title":"Cancer Discov."},{"key":"352_CR45","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1158\/1078-0432.CCR-17-1261","volume":"24","author":"TL Whiteside","year":"2018","unstructured":"Whiteside, T. L. Head and neck carcinoma immunotherapy: facts and hopes. Clin. Cancer Res. 24, 6\u201313 (2018).","journal-title":"Clin. Cancer Res."},{"key":"352_CR46","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1080\/14737140.2017.1316197","volume":"17","author":"TL Whiteside","year":"2017","unstructured":"Whiteside, T. L. Targeting adenosine in cancer immunotherapy: a review of recent progress. Expert. Rev. Anticancer Ther. 17, 527\u2013535 (2017).","journal-title":"Expert. Rev. Anticancer Ther."},{"key":"352_CR47","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.it.2017.05.005","volume":"38","author":"LM Snell","year":"2017","unstructured":"Snell, L. M., McGaha, T. L. & Brooks, D. G. Type I interferon in chronic virus infection and cancer. Trends Immunol. 38, 542\u2013557 (2017).","journal-title":"Trends Immunol."},{"key":"352_CR48","doi-asserted-by":"publisher","first-page":"2772","DOI":"10.4049\/jimmunol.1003208","volume":"186","author":"S Terawaki","year":"2011","unstructured":"Terawaki, S. et al. IFN-alpha directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J. Immunol. 186, 2772\u20132779 (2011).","journal-title":"J. Immunol."},{"key":"352_CR49","doi-asserted-by":"publisher","first-page":"djv435","DOI":"10.1093\/jnci\/djv435","volume":"108","author":"F Sabbatino","year":"2016","unstructured":"Sabbatino, F. et al. Antitumor activity of BRAF inhibitor and IFNalpha combination in BRAF-mutant melanoma. J. Natl. Cancer Inst. 108, djv435 (2016).","journal-title":"J. Natl. Cancer Inst."},{"key":"352_CR50","doi-asserted-by":"publisher","first-page":"ra50","DOI":"10.1126\/scisignal.2004998","volume":"7","author":"D Levin","year":"2014","unstructured":"Levin, D. et al. Multifaceted activities of type I interferon are revealed by a receptor antagonist. Sci. Signal. 7, ra50 (2014).","journal-title":"Sci. Signal."},{"key":"352_CR51","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/nature13554","volume":"511","author":"NG Sandler","year":"2014","unstructured":"Sandler, N. G. et al. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature 511, 601\u2013605 (2014).","journal-title":"Nature"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0352-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0352-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0352-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:03:56Z","timestamp":1684616636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-018-0352-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,17]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["352"],"URL":"https:\/\/doi.org\/10.1038\/s41416-018-0352-y","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,17]]},"assertion":[{"value":"1 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethics Committee of the Ninth People\u2019s Hospital, Shanghai Jiao Tong University School of Medicine (Shanghai, China), and informed consent was obtained from all patients (reference number:2018077). The animal study was also approved by Ethics Committee of the Ninth People\u2019s Hospital. The study was performed in accordance to the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication was obtained from all authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was supported by grants from the National Natural Science Foundation of China (Grant No. 81472516), the Natural Science Foundation of Shanghai (No. 14ZR1424200), China Postdoctoral Science Foundation (2018M632141) and the Shanghai Leading Academic Discipline Project (No. S30206).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Note"}}]}}